Home Healthcare Healthcare Services Biopharmaceutical Contract Manufacturing Market

Biopharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Service (Process Development, Analytical & QC studies, Fill & Finish Operations, Packaging & Labelling, Others), By Source (Mammalian, Non-mammalian), By Drug Type (Biologics, Biosimilars), By Product Type (Drug Substance, Finished Drug Product), By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Neurology, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: February 12, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Biopharmaceutical Contract Manufacturing Market, By Service 2022-2034 (USD MILLION/ Units)
    1. Process Development
      1. Upstream
      2. Downstream
    2. Analytical & QC studies
    3. Fill & Finish Operations
    4. Packaging & Labelling
    5. Others
  2. Biopharmaceutical Contract Manufacturing Market, By Source 2022-2034 (USD MILLION/ Units)
    1. Mammalian
    2. Non-mammalian
  3. Biopharmaceutical Contract Manufacturing Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Biologics
      1. Monoclonal antibodies
      2. Recombinant Proteins
      3. Vaccines
      4. Cell and Gene Therapy
      5. Therapeutic Peptides & Proteins
        1. Others
    2. Biosimilars
  4. Biopharmaceutical Contract Manufacturing Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Drug Substance
    2. Finished Drug Product
  5. Biopharmaceutical Contract Manufacturing Market, By Therapeutic Area 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Autoimmune Diseases
    3. Infectious Diseases
    4. Cardiovascular Diseases
    5. Metabolic Diseases
    6. Neurology
    7. Others
  6. Regional Biopharmaceutical Contract Manufacturing Market
    1. North America
      1. North America Biopharmaceutical Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
      2. North America Biopharmaceutical Contract Manufacturing Market By Source 2022-2034 (USD MILLION/ Units)
        1. Mammalian
        2. Non-mammalian
      3. North America Biopharmaceutical Contract Manufacturing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        2. Biosimilars
      4. North America Biopharmaceutical Contract Manufacturing Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drug Substance
        2. Finished Drug Product
      5. North America Biopharmaceutical Contract Manufacturing Market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Cardiovascular Diseases
        5. Metabolic Diseases
        6. Neurology
        7. Others
      6. U.S.
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      7. Canada
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
    2. Europe
      1. Europe Biopharmaceutical Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
      2. Europe Biopharmaceutical Contract Manufacturing Market By Source 2022-2034 (USD MILLION/ Units)
        1. Mammalian
        2. Non-mammalian
      3. Europe Biopharmaceutical Contract Manufacturing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        2. Biosimilars
      4. Europe Biopharmaceutical Contract Manufacturing Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drug Substance
        2. Finished Drug Product
      5. Europe Biopharmaceutical Contract Manufacturing Market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Cardiovascular Diseases
        5. Metabolic Diseases
        6. Neurology
        7. Others
      6. U.K.
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      7. Germany
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      8. France
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      9. Spain
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      10. Italy
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      11. Russia
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      12. Nordic
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      13. Benelux
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      14. Rest of Europe
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
    3. APAC
      1. APAC Biopharmaceutical Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
      2. APAC Biopharmaceutical Contract Manufacturing Market By Source 2022-2034 (USD MILLION/ Units)
        1. Mammalian
        2. Non-mammalian
      3. APAC Biopharmaceutical Contract Manufacturing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        2. Biosimilars
      4. APAC Biopharmaceutical Contract Manufacturing Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drug Substance
        2. Finished Drug Product
      5. APAC Biopharmaceutical Contract Manufacturing Market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Cardiovascular Diseases
        5. Metabolic Diseases
        6. Neurology
        7. Others
      6. China
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      7. Korea
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      8. Japan
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      9. India
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      10. Australia
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      11. Taiwan
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      12. South East Asia
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      13. Rest of Asia-Pacific
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
    4. Middle East and Africa
      1. Middle East and Africa Biopharmaceutical Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
      2. Middle East and Africa Biopharmaceutical Contract Manufacturing Market By Source 2022-2034 (USD MILLION/ Units)
        1. Mammalian
        2. Non-mammalian
      3. Middle East and Africa Biopharmaceutical Contract Manufacturing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        2. Biosimilars
      4. Middle East and Africa Biopharmaceutical Contract Manufacturing Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drug Substance
        2. Finished Drug Product
      5. Middle East and Africa Biopharmaceutical Contract Manufacturing Market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Cardiovascular Diseases
        5. Metabolic Diseases
        6. Neurology
        7. Others
      6. UAE
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      7. Turkey
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      8. Saudi Arabia
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      9. South Africa
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      10. Egypt
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      11. Nigeria
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      12. Rest of MEA
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
    5. LATAM
      1. LATAM Biopharmaceutical Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
      2. LATAM Biopharmaceutical Contract Manufacturing Market By Source 2022-2034 (USD MILLION/ Units)
        1. Mammalian
        2. Non-mammalian
      3. LATAM Biopharmaceutical Contract Manufacturing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        2. Biosimilars
      4. LATAM Biopharmaceutical Contract Manufacturing Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drug Substance
        2. Finished Drug Product
      5. LATAM Biopharmaceutical Contract Manufacturing Market By Therapeutic Area 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Infectious Diseases
        4. Cardiovascular Diseases
        5. Metabolic Diseases
        6. Neurology
        7. Others
      6. Brazil
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      7. Mexico
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      8. Argentina
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      9. Chile
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      10. Colombia
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
      11. Rest of LATAM
        1. Process Development
          1. Upstream
          2. Downstream
        2. Analytical & QC studies
        3. Fill & Finish Operations
        4. Packaging & Labelling
        5. Others
        6. Mammalian
        7. Non-mammalian
        8. Biologics
          1. Monoclonal antibodies
          2. Recombinant Proteins
          3. Vaccines
          4. Cell and Gene Therapy
          5. Therapeutic Peptides & Proteins
            1. Others
        9. Biosimilars
        10. Drug Substance
        11. Finished Drug Product
        12. Oncology
        13. Autoimmune Diseases
        14. Infectious Diseases
        15. Cardiovascular Diseases
        16. Metabolic Diseases
        17. Neurology
        18. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.